Biogen Inc.

BIIB · NASDAQ · USD

PoliticiansInstitutionalInsiders

Current holders

Politician	Disclosed
Donald Trump R · EXECUTIVE	net −$14K – $14K 2 disclosures · 1 bought / 1 sold · last Jun 12, 2026
Ro Khanna D · HOUSE · CA	−$386K – $545K −$448K – $602K today 65 filings · last May 27, 2026
Maria Elvira Salazar R · HOUSE · FL	−$13K – $114K −$17K – $143K today 5 filings · last Sep 24, 2026
Alan S. Lowenthal D · HOUSE · CA	$1 – $49K −$1K – $28K today 2 filings · last Jul 23, 2015
Gilbert Ray Cisneros, Jr. D · HOUSE · CA	−$40K – $72K −$39K – $74K today 8 filings · last Jun 5, 2026
Sheldon Whitehouse D · SENATE · RI	−$75K – $107K −$72K – $71K today 10 filings · last Mar 22, 2019
Robert Bresnahan R · HOUSE · PA	−$13K – $29K −$29K – $54K today 3 filings · last May 15, 2025
Gary J. Palmer R · HOUSE · AL	−$13K – $29K −$9K – $24K today 3 filings · last Oct 5, 2018
Alan Armstrong R · SENATE · OK	$1K – $15K $1K – $20K today 1 filing · last Mar 27, 2026
Josh Gottheimer D · HOUSE · NJ	−$55K – $71K −$55K – $60K today 9 filings · last Mar 17, 2022

Recent transactions

Trades from Aug 29, 2023 – Sep 24, 2026

Politician	Type	Filed after	Amount
Maria Elvira Salazar R · HOUSE · FL-27	Sell	13 days Sep 24, 2026 → Oct 7, 2026	≥$1K
Kevin Hern R · HOUSE · OK-1	Sell	14 days Aug 18, 2026 → Sep 1, 2026	≥$1K
Donald Trump R · EXECUTIVE	Sell	71 days Jun 12, 2026 → Aug 22, 2026	≥$1K
Alan Armstrong R · SENATE · OK	Buy	116 days Mar 27, 2026 → Jul 21, 2026	≥$1K
Maria Elvira Salazar R · HOUSE · FL-27	Sell	35 days Jun 2, 2026 → Jul 7, 2026	≥$15K
Gilbert Ray Cisneros, Jr. D · HOUSE · CA-31	Buy	27 days Jun 5, 2026 → Jul 2, 2026	≥$1K
Donald Trump R · EXECUTIVE	Buy	51 days May 11, 2026 → Jul 1, 2026	≥$1K
Ro Khanna D · HOUSE · CA-17	Sell	13 days May 27, 2026 → Jun 9, 2026	≥$1K
Ro Khanna D · HOUSE · CA-17	Buy	25 days May 15, 2026 → Jun 9, 2026	≥$1K
Maria Elvira Salazar R · HOUSE · FL-27	Buy	27 days May 12, 2026 → Jun 8, 2026	≥$1K

Congressional trading data provided by QuiverQuant

Institutional

Investors holding

1,103

13F shares

143.5M

Total invested

$31.0B

Ownership

97.2%

New positions

129

Closed positions

Increased positions

552

Reduced positions

305

Put/Call ratio

0.76

Holder	Reported	Shares	Value	Δ Qtr
FMR LLC	8/13/2026	18.2M	$3.9B	+42.24%
BLACKROCK, INC.	8/7/2026	16M	$3.5B	+0.07%
PRIMECAP MANAGEMENT CO/CA/	8/14/2026	15.2M	$3.3B	+2.69%
VANGUARD CAPITAL MANAGEMENT LLC	8/13/2026	9.7M	$2.1B	+1.19%
STATE STREET CORP	9/22/2026	7.3M	$1.6B	+2.46%
VANGUARD PORTFOLIO MANAGEMENT LLC	8/13/2026	6.6M	$1.4B	+1.12%
GEODE CAPITAL MANAGEMENT, LLC	8/12/2026	4.4M	$957.9M	+2.46%
WELLINGTON MANAGEMENT GROUP LLP	8/14/2026	3.1M	$673.6M	+5.26%
NORGES BANK	8/12/2026	2.6M	$557.4M	—
MORGAN STANLEY	8/13/2026	2.4M	$521.0M	+11.07%
AQR CAPITAL MANAGEMENT LLC	8/14/2026	1.9M	$416.9M	+0.69%
JPMORGAN CHASE & CO	8/12/2026	1.8M	$394.9M	−9.57%
INVESCO LTD.	8/14/2026	1.8M	$389.8M	+3.36%
AMUNDI	8/11/2026	1.5M	$327.7M	+91.80%
LEGAL & GENERAL GROUP PLC	8/14/2026	1.5M	$322.6M	+10.63%
NORTHERN TRUST CORP	8/13/2026	1.4M	$308.9M	−1.18%
BOSTON PARTNERS	8/4/2026	1.3M	$272.8M	−25.68%
UBS ASSET MANAGEMENT AMERICAS INC	8/13/2026	1.3M	$271.2M	−8.89%
GOLDMAN SACHS GROUP INC	8/14/2026	1.2M	$265.8M	+17.06%
DIMENSIONAL FUND ADVISORS LP	8/11/2026	1.1M	$248.2M	+6.44%
PACER ADVISORS, INC.	8/13/2026	1.1M	$242.6M	+70.04%
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	8/14/2026	1.1M	$241.5M	−2.76%
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P.	8/14/2026	1.1M	$241.5M	—
BANK OF AMERICA CORP /DE/	8/14/2026	1.1M	$241.2M	−3.47%
UBS GROUP AG	8/13/2026	1M	$222.6M	+96.80%

Insider transactions

Insider	Type	Transacted	Price	Date
Godbout Sean	F-INKIND	8	$219.88	Oct 2
Godbout Sean	M-EXEMPT	27	—	Oct 2
Godbout Sean	M-EXEMPT	27	—	Oct 2
Godbout Sean	A-AWARD	985	—	Oct 1

Analyst consensus

Buy49 analysts

Bearish · 1 · Hold · 16 · Bullish · 32

Earnings history

	EPS	Estimate
Q3 2024	$4.08	$3.77	Beat
Q4 2024	$3.44	$3.43	Beat
Q1 2025	$3.02	$2.90	Beat
Q2 2025	$5.47	$3.90	Beat
Q3 2025	$4.81	$3.88	Beat
Q4 2025	$1.99	$1.63	Beat
Q1 2026	$3.57	$3.05	Beat
Q2 2026	$3.60	$2.94	Beat

Peers

Company overview

IPO dateSep 17, 1991

CEOChristopher A. Viehbacher

Employees7,500

SectorHealthcare

IndustryDrug Manufacturers - General

CountryUS

ExchangeNASDAQ Global Select

Websitewww.biogen.com

Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addressing multiple sclerosis (MS), such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA. For spinal muscular atrophy (SMA), Biogen provides SPINRAZA, while FUMADERM is available for the treatment of plaque psoriasis. Among its other key offerings is ADUHELM, specifically developed for Alzheimer's disease. The company also markets a selection of biosimilar drugs, including BENEPALI (an etanercept biosimilar akin to ENBREL), IMRALDI (an adalimumab biosimilar comparable to HUMIRA), and FLIXABI (an infliximab biosimilar referencing REMICADE). Further extending its therapeutic reach, Biogen supplies RITUXAN, prescribed for conditions like non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, certain types of ANCA-associated vasculitis, and pemphigus vulgaris. RITUXAN HYCELA targets non-Hodgkin's lymphoma and CLL, and GAZYVA is utilized for CLL and follicular lymphoma. OCREVUS addresses both relapsing and primary progressive forms of MS, complementing the company's broader efforts in anti-CD20 therapies. The company maintains a robust research and development pipeline, featuring numerous investigational therapies. These candidates are designed to tackle a wide spectrum of conditions, including multiple sclerosis and neuroimmunological disorders (e.g., BIIB135, BIIB061, BIIB091, BIIB107), Alzheimer's disease and other forms of dementia (e.g., Aducanumab, Lecanemab, BIIB076, BIIB080), neuromuscular disorders (e.g., BIIB067, BIIB078, BIIB105, BIIB100, BIIB110), Parkinson's disease and related movement disorders (e.g., BIIB124, BIIB094, BIIB118, BIIB101, BIIB122), neuropsychiatric conditions (e.g., BIIB125, BIIB104), immunology-related illnesses (e.g., Dapirolizumab pegol, BIIB059), acute neurological events (e.g., BIIB093, BIIB131), and neuropathic pain (e.g., BIIB074). Additionally, several biosimilar candidates, such as BYOOVIZ, BIIB800, and SB15, are progressing through various developmental stages. Biogen actively engages in strategic collaborations and licensing arrangements with various partners, including Acorda Therapeutics, Inc., Alkermes Pharma Ireland Limited, Denali Therapeutics Inc., Eisai Co., Ltd., Genentech, Inc., Neurimmune SubOne AG, Ionis Pharmaceuticals, Inc., Samsung Bioepis Co., Ltd., Sangamo Therapeutics, Inc., and Sage Therapeutics, Inc. Established in 1978, Biogen Inc. maintains its corporate headquarters in Cambridge, Massachusetts.

Athenic provides research and information tools for educational purposes only and is not a registered investment adviser or broker-dealer. Nothing on this page is investment advice or a recommendation to buy or sell any security. Market data may be delayed. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal.